Free Trial

Knight Therapeutics (GUD) Stock Forecast & Price Target

C$5.41
-0.04 (-0.73%)
(As of 06/20/2024 ET)

Knight Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

C$6.75
24.77% Upside
High ForecastC$7.50
Average ForecastC$6.75
Low ForecastC$5.75
TypeCurrent Forecast
6/22/23 to 6/21/24
1 Month Ago
5/23/23 to 5/22/24
3 Months Ago
3/24/23 to 3/23/24
1 Year Ago
6/22/22 to 6/22/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetC$6.75C$6.75C$6.44C$5.97
Forecasted Upside24.77% Upside21.95% Upside26.58% Upside23.48% Upside
Get Knight Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

GUD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GUD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Knight Therapeutics Stock vs. The Competition

TypeKnight TherapeuticsMedical Companies
Consensus Rating Score
2.67
2.70
Consensus RatingModerate BuyModerate Buy
News Sentiment RatingNeutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/10/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetC$5.40 ➝ C$5.75-3.04%
3/22/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperformC$6.50 ➝ C$7.00+32.58%
3/6/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperformC$7.00 ➝ C$7.50+36.61%
3/24/2023National Bank Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Leno
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform Market Weight ➝ Sector Perform Market Weight
3/24/2023National Bankshares
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Sector PerformC$7.75 ➝ C$6.00+32.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:54 AM ET.

GUD Forecast - Frequently Asked Questions

What is Knight Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Knight Therapeutics is C$6.75, with a high forecast of C$7.50 and a low forecast of C$5.75. The consensus rating for Knight Therapeutics stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for GUD. Learn more on GUD's analyst rating history.

Do Wall Street analysts like Knight Therapeutics more than its competitors?

Analysts like Knight Therapeutics less than other "medical" companies. The consensus rating score for Knight Therapeutics is 2.67 while the average consensus rating score for "medical" companies is 2.70. Learn more on how GUD compares to other companies.

Does Knight Therapeutics's stock price have much upside?

According to analysts, Knight Therapeutics's stock has a predicted upside of 21.95% based on their 12-month stock forecasts.

What analysts cover Knight Therapeutics?

Knight Therapeutics has been rated by research analysts at Stifel Nicolaus in the past 90 days.


Stock Forecasts and Research Tools

This page (TSE:GUD) was last updated on 6/21/2024 by MarketBeat.com Staff

From Our Partners